Following on from a strong FY trading update, Diaceutics has released its FY21 results. These are indicative of a business that's adapted to its new model with exceptional pace, and which is ready to grow its top line while enjoying significant operating leverage and good cash conversion. With the majority of revenue now coming from the platform, which only launched in October 2020, we look forward to more recurring revenue and higher quality earnings than ever before.
23 Mar 2022
Diaceutics - FY Results - March 22
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Diaceutics - FY Results - March 22
Diaceutics Plc (DXRX:LON) | 104 -0.5 (-0.5%) | Mkt Cap: 87.7m
- Published:
23 Mar 2022 -
Author:
Oliver Juggins -
Pages:
8
Following on from a strong FY trading update, Diaceutics has released its FY21 results. These are indicative of a business that's adapted to its new model with exceptional pace, and which is ready to grow its top line while enjoying significant operating leverage and good cash conversion. With the majority of revenue now coming from the platform, which only launched in October 2020, we look forward to more recurring revenue and higher quality earnings than ever before.